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Background: Pegloticase is approved in the US for treatment of refractory chronic gout. Since chronic kidney
disease (CKD) is common in these patients, we conducted a post-hoc analysis of 2 replicate phase 3 trials and the
subsequent open-label extension study to determine the effects of pegloticase on renal function in patients with
CKD stages 3 and 4, as well as the effects of renal dysfunction on pegloticase efficacy and safety.
Findings: Patients with renal insufficiency were randomized to pegloticase 8 mg every 2 weeks (n = 42),
pegloticase 8 mg every 4 weeks (n = 41), or placebo (n = 20) for 6 months as defined by the study protocols. Renal
function was assessed by estimated glomerular filtration rate (eGFR). All patients completing the randomized trials
could participate in an open-label extension study for a further 2.5 years. Uric acid response, the primary end point
in the trials, was plasma uric acid <6.0 mg/dl for 80% of months 3 and 6.
Mean eGFR in both pegloticase dosing cohorts remained constant over the randomized treatment phase and
long-term open-label extension study. The number of patients achieving uric acid response was similar across CKD
stages (32% stage 1, 23% stage 2, 35% stage 3, and 39% stage 4, respectively, P = 0.3). There was no difference in
the pegloticase safety profile based on CKD stage.
Conclusions: Pegloticase treatment does not impact eGFR in CKD patients and response to pegloticase is
independent of CKD stage.
Trial registration: Clinical trial identifier: NCT00325195
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Background
Pegloticase is a novel recombinant, mammalian uricase
covalently linked to monomethoxypolyethylene glycol,
and is approved in the United States for treatment of re-
fractory chronic gout (RCG) [1-4]. Pegylation enables
the conjugate to have a prolonged elimination half-life
of up to 14 days following intravenous infusion [4].
Pegloticase rapidly degrades plasma urate to allantoin, a* Correspondence: Robert.Yood@reliantmedicalgroup.org
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reproduction in any medium, provided the ormore soluble compound that is easily excreted by the
kidneys [2-4]. Due to the low plasma urate level, extra-
vascular urate moves into the plasma compartment
down its concentration gradient where it is available for
degradation by pegloticase. Among patients who respond
to therapy, this process is believed to engender urate
crystal dissolution within soft tissue and peri-articular
structures, with eventual normalization of body urate
stores, and resolution of RCG signs and symptoms [3-6].
The prevalence of gout is highest in individuals >60
years of age [7], who also often have chronic kidney dis-
ease (CKD) [8,9]. Indeed, results of a recent retrospect-
ive database analysis indicated that a large proportiontd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[10]. While gout and CKD are likely comorbidities with
a shared etiology, causative mechanistic factors have yet
to be elucidated. It is known, however, that CKD is an
independent risk factor for chronic gout [11,12] and,
vice versa, that hyperuricemia and gout are risk factors
for CKD [13-18]. From a clinical practice perspective,
CKD limits the use of some urate-lowering therapies
and complicates symptomatic treatment with nonsteroidal
anti-inflammatory drugs and colchicine [19], although
colchicine remains a viable treatment option for acute
gout providing dosage reductions are made for moderate-
to-severe renal impairment [20,21].
We conducted a post-hoc subgroup analysis to deter-
mine the effects, if any, of pegloticase on renal function in
patients with CKD stages 3 and 4 (estimated glomerular
filtration rate [eGFR], 30–59 ml/min/1.73 m2 and 15–
29 ml/min/1.73 m2, respectively [9]). Conversely, we
also evaluated the effects renal dysfunction may have
on pegloticase efficacy and safety.Methods
Summary of study design and entry criteria
Data were retrospectively analyzed from 2 randomized,
placebo-controlled, replicate phase 3 clinical trials (n = 212)
of pegloticase use over 6 months in patients with RCG to
determine the effects of pegloticase on renal function. A
total of 49% of patients from the randomized controlled
trials (RCTs) met the criteria for stages 3 and 4 CKD [9].
Since the designs of the phase 3 trials were identical, data
were pooled to enable an integrated comparison of the
treatment regimens. The effect of long-term pegloticase
treatment on renal function was evaluated using data from
patients with CKD from the RCTs who entered the open-
label extension (OLE) study.
The full methodology of the 2 randomized, double-
blind, multicenter, placebo-controlled trials (C0405 and
C0406; NCT00325195) has been published previously [6].
Briefly, patients were ≥18 years of age and had RCG based
on a baseline serum uric acid of ≥8.0 mg/dl and ≥1 of
the following: ≥3 self-reported gout flares during the
previous 18 months; ≥1 tophi; and gouty arthropathy
(defined clinically or radiographically as joint damage
caused by gout). Patients also had contraindication to treat-
ment with allopurinol or history of failure to normalize uric
acid despite ≥3 months of treatment with the maximum
medically appropriate allopurinol dose [6]. Patients receiv-
ing dialysis were excluded. Both studies were conducted in
accordance with the ethical principles of the Declaration of
Helsinki and received institutional review board ap-
proval at each site (local) or by a central institutional re-
view board (IntegReview, Austin, Texas). All patients
gave written, informed consent [6].Treatment regimens
Patients in the RCTs were assigned in a 2:2:1 ratio to re-
ceive intravenous infusions of pegloticase 8 mg every 2
weeks, pegloticase 8 mg every 4 weeks (alternating with
placebo to maintain blinding), or placebo for 24 weeks.
After completing the study, subjects were given the option
of continuing active treatment for up to 2.5 years through
a follow-on OLE study. Dose adjustment was permitted
twice during the OLE study.
Renal function
The primary end point in this post-hoc analysis was the
impact of up to 6 months of pegloticase on renal function
in patients with CKD stages 3 and 4, as defined by the
National Kidney Foundation Kidney Disease Outcomes
Quality Initiative [9]. Renal function was assessed by
eGFR using the 4-variable Modification of Diet in Renal
Disease (MDRD) formula: eGFR (ml/min/1.73 m2) =
186 × (SCr)-1.154 × (age)-0.203 × (0.742 if female) × (1.212
if black/African American), where SCr is serum creatinine
in mg/dl and age in years [22]. eGFR was calculated at
screening (week 0) and at protocol-defined time points
(weeks 7, 13, 19, and 25 post-randomization). For patients
who participated in the OLE study, eGFR was calculated
at weeks 13, 25, 37, 53, 65, 77, 89, and 101 following start
of treatment in the OLE treatment phase. CKD stage was
based solely on the eGFR calculation.
Absolute and relative changes from baseline (screening)
in eGFR were calculated as follows:
(1)Absolute change =minimum eGFR post-screening –
screening eGFR.
(2) Percent change = 100 × (minimum eGFR post-
screening – screening eGFR)/screening eGFR.
(3) Percent change in eGFR was further categorized as
follows: Category 1, no change (Δ) or improvement;
Category 2, 0 <Δ ≤ 10%; Category 3, 10 <Δ ≤ 20%;
Category 4, 20 < Δ ≤ 30%; Category 5, 30 <Δ ≤ 40%;
Category 6, 40 < Δ ≤ 50%; and Category 7, Δ > 50%.
Responders
Uric acid response was the primary end point in the
pegloticase phase 3 trials. A responder was defined as a
patient with plasma uric acid level <6.0 mg/dl for 80% of
the time during months 3 and 6 combined.
Analysis population
Clinical outcomes were assessed in the modified intention-
to-treat population (mITT), defined as all patients with
RCG who received ≥1 infusion of study medication.
Statistical analysis
Continuous data are presented as the mean ± standard
deviation (SD) or median and range, and categorical data
Table 1 CKD stage definition and summary overall and by randomized treatment group per clinical trial*





PGL q2wks PGL q4wks Placebo Overall PGL q2wks PGL q4wks Placebo Overall
(n = 43) (n = 41) (n = 20) (n = 104) (n = 42) (n = 43) (n = 23) (n = 108)
1 ≥90 8 (18.6) 6 (14.6) 3 (15.0) 17 (16.3) 9 (21.4) 5 (11.6) 3 (13.0) 17 (15.7)
2 60-89 14 (32.6) 12 (29.3) 4 (20.0) 30 (28.8) 12 (28.6) 19 (44.2) 13 (56.5) 44 (40.7)
3 30-59 15 (34.9) 19 (46.3) 11 (55.0) 45 (43.3) 17 (40.5) 13 (30.2) 5 (21.7) 35 (32.4)
4 15-29 6 (14.0) 4 (9.8) 2 (10.0) 12 (11.5) 4 (9.5) 5 (11.6) 2 (8.7) 11 (10.2)
5 <15 (or dialysis) 0 0 0 0 0 0 0 0
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PGL, pegloticase; q2wks, every 2 weeks; q4wks, every 4 weeks.
*Based on the intent to treat analysis data set; that is, all randomized patients who received at least one dose of treatment.
†As described by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.
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dom intercept) model was used to analyze longitudinal
measures of eGFR assuming an unstructured covariance
matrix for the random intercept effect [23].
Treatment (i.e., pegloticase every 2 weeks and every
4 weeks versus placebo), visit (week), treatment × visit,
age (years), sex (female versus male) and race/ethnicity
(black/African American, Hispanic/Latino and other
versus white) were included as fixed effects, while sub-
ject was included as a random effect. Two-way interac-
tions of treatment with age, sex, and race/ethnicity
were tested to evaluate whether the overall impact of
treatment was differentially affected by age, sex, or
race/ethnicity. Absolute and percentage change in
eGFR was compared between groups using general


































Figure 1 Observed mean eGFR (± SD) over time by treatment group
each of the randomized treatment groups (pegloticase infused every 2 we
placebo) during the 6-month trials. PGL = pegloticase, SD = standard deviatResults
Study populations
Baseline eGFR and CKD data for the full population of
the RCTs is shown in Table 1. Among these patients,
103 (49%) had CKD stage 3 (n = 80) or 4 (n = 23); no pa-
tients had CKD stage 5 by protocol exclusion. Forty-two
of 103 patients (41%) received pegloticase 8 mg every 2
weeks, 41 patients (40%) received pegloticase 8 mg every
4 weeks, and 20 patients (19%) received placebo.
Baseline characteristics were comparable across the
CKD stage 3 and 4 cohort for each of the 3 study arms.
For the full CKD stage 3/4 cohort, mean age was
61.7 years, 71% were men, 67% were white, and 18% were
black or African American. Mean eGFR at screening was
40.4 ml/min/1.73 m2 and 40.1 ml/min/1.73 m2 in the
pegloticase biweekly and monthly arms, respectively,
versus 43.3 ml/min/1.73 m2 in the placebo arm (P = 0.6).19 25
domization
in the RCTs. Mean eGFR was determined every 6 weeks for patients in
eks, pegloticase infused every 4 weeks alternating with placebo, and
ion, eGFR = estimated glomerular filtration rate.
Table 2 Absolute and percentage change in eGFR in patients with CKD stages 3 and 4
Parameter PGL q2wks (n = 42) PGL q4wks (n = 41) Placebo (n = 20) P value*
Absolute change in eGFR
Mean (SD) −2.8 (8.2) −1.1 (11.2) −2.7 (8.1) 0.607
Median (min, max) −4.12 (−19.6, 19.7) −2.63 (−15.2, 54.6) −2.54 (−18.6, 16.1)
Percent change in eGFR
Mean (SD) −4.2 (24.5) −4.4 (27.3) −5.8 (21.2) 0.853
Median (min, max) −10.4 (−45.5, 94.2) −9.6 (−57.7, 106.6) −6.1 (−46.0, 52.3)
eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; PGL, pegloticase; q2wks, every 2 weeks; q4wks, every 4 weeks; SD, standard deviation.
*A general linear model F-test, adjusted for age, sex, and race/ethnicity, was used to assess the overall impact of treatment.
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55.4 years, 81.6% were men, 67.5% were white, and 13%
were black.
Of the 103 patients with CKD stage 3 or 4 in the RCTs,
76 (74%) participated in the OLE study. Two patients re-
ceived no pegloticase treatment and were excluded from
further analysis, 43 (58%) received pegloticase 8 mg every
2 weeks, and 31 (42%) received pegloticase 8 mg every 4
weeks. No statistically significant difference in patient
demographics was observed between treatment groups
entering the OLE study. Mean age was 62 years, 65% of
patients were men, and 70% of patients were white.
Phase 3 clinical trials
Mean eGFR remained constant in the 3 study arms over
the 25-week randomized treatment phase (Figure 1).
Change in eGFR was not differentially affected by treat-
ment (treatment × time interaction: P = 0.277), inde-
pendent of age, sex, and race/ethnicity. In addition, no
discontinuation pattern was observed that may have
biased the treatment effect toward the null hypothesis
of no treatment difference. Mean absolute and percent-
age changes from baseline in eGFR for individuals were
consistent with overall findings from the linear mixed
























Figure 2 Percentage of patients with a change in eGFR by categories
baseline in the minimum eGFR observed at post-randomization visit. Categ
decline. Percentages are presented by randomized treatment group. PGL =third of patients in all groups had either no change or
an improvement in renal function during the 25-week
randomized treatment phase, and approximately one-half
of patients in all groups had no more than a 10% decline
in renal function (Figure 2).
No difference was detected in responder rates to pegloti-
case therapy by CKD stage. The percentages of responders
in subgroups with CKD stage 1, stage 2, stage 3, and stage
4 were 32%, 23%, 35%, and 39%, respectively, (P = 0.3).
Responders had statistically significant lower mean eGFR
compared with nonresponders at baseline (59.1 ± 25.3 ml/
min/1.73 m2 versus 63.3 ± 24.6 ml/min/1.73 m2) and at
6 months (61.5 ± 24.6 ml/min/1.73 m2 versus 63.8 ±
25.1 ml/min/1.73 m2; P = 0.026).OLE study
Mean (± SD) eGFR at week 1 of the OLE study (after a
gap in therapy between trials) was 41.9 ± 14.0 ml/min/
1.73 m2 for patients who received pegloticase 8 mg every
2 weeks and 45.3 ± 12.4 ml/min/1.73 m2 for patients who
received 8 mg pegloticase every 4 weeks (P = 0.299). Total
mean (± SD) treatment duration (from RCT randomization)
was also similar between the pegloticase 8 mg every












of change. Change was calculated as the percentage change from
ories of change were derived as a proxy for severity of renal function
pegloticase.
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weeks [range, 12–123 weeks], respectively, P = 0.7).
Mean (± SD) eGFR at week 101 in the OLE study was
46.0 ± 13.3 ml/min/1.73 m2 in patients receiving pegloti-
case biweekly compared with 40.6 ± 14.9 ml/min/1.73 m2
in patients receiving pegloticase monthly (P = 0.3). No
change in eGFR was detected with respect to time
(treatment × time interaction: P = 0.9), independent of
age, sex, and race/ethnicity.
Safety and tolerability
When assessed for the full safety population of patients
in the RCTs, gout flares and infusion reactions were the
2 most common adverse events. Multiple subgroup ana-
lyses from the RCTs have confirmed this finding. Fur-
ther, there were no differences in the pegloticase safety
profile based on CKD stage and no new safety signals
were detected in this cohort.
Discussion
This post-hoc subgroup analysis has revealed several new
findings of relevance to clinical management of RCG.
First, patients with stage 3 or 4 CKD had no clinically
meaningful changes in renal function with up to 6 months
of pegloticase therapy. Similarly, no changes in renal func-
tion were observed in patients who participated in the
long-term OLE study for a total mean period of 1.5 years
of pegloticase therapy. Second, pegloticase efficacy and
safety were not affected by renal function status. Finally,
response to pegloticase was independent of CKD stage.
While there was a statistically significant trend indicating
that responders had lower eGFRs than nonresponders,
change in eGFR over time was not different as a function
of responder status.
One strength of the present analysis is the utilization
of prospectively collected data derived from randomized
clinical trials that featured a placebo arm. However, the
analysis is limited by established drawbacks of retrospect-
ive data analyses. In addition, the phase 3 clinical trials
were not powered to detect changes in renal function
across randomized treatment groups.
Normalization of hyperuricemia for extended periods
in patients with renal impairment may have clinical impli-
cations. Urate-lowering with allopurinol and febuxostat
has been associated with preservation of renal function in
patients with gout; results reported here for pegloticase
are consistent with these previous findings [24-26]. While
no change or decrement in mean eGFR was associated
with pegloticase therapy during the randomized and OLE
studies, the slow rate of progression of CKD means that a
larger sample size must be followed for a longer period of
time to confirm this observation. Rarely, hypouricemia
resulting from mutations in URAT1 and GLUT9 has
been associated with exercise-induced acute kidney injury.Mechanistically this relationship is poorly understood
[27-29] and it should be noted that pegloticase has no
effect on urate/anion transporters. One patient in the
pegloticase trials developed acute kidney injury attributed
to sepsis and chronic renal insufficiency with no evidence
for a relationship with hypouricemia.
Conclusion
In conclusion, these data provide support for the use of
pegloticase in the management of patients with RCG
and comorbid CKD stages 3 and 4 at the approved dosage
of 8 mg every 2 weeks.
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